Who are ACS patients treated with OAP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): LCZ 696.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acs-patients-treated-with-oap.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ACS patients treated with OAP — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ACS patients treated with OAP (ACS patients treated with OAP) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin receptor-neprilysin inhibitor. Area: Cardiovascular.

phase 2 Angiotensin receptor-neprilysin inhibitor Angiotensin II receptor, Neprilysin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

ACS patients treated with OAP (ACS patients treated with OAP) — AstraZeneca. OAP is an angiotensin receptor-neprilysin inhibitor.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ACS patients treated with OAP TARGET	ACS patients treated with OAP	AstraZeneca	phase 2	Angiotensin receptor-neprilysin inhibitor	Angiotensin II receptor, Neprilysin
LCZ 696	LCZ 696	National Medical Research Center for Cardiology, Ministry of Health of Russian Federation	marketed	Angiotensin receptor-neprilysin inhibitor (ARNI)	Angiotensin II type 1 receptor (AT1R); Neprilysin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Angiotensin receptor-neprilysin inhibitor class)

AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACS patients treated with OAP — Competitive Intelligence Brief. https://druglandscape.com/ci/acs-patients-treated-with-oap. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab